Maria-Georgiana Gavrilă

Dr. Maria-Georgiana Gavrilă

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2026 in Cells
Verified
Journal Article
Open access
PDF file
MGMaria-Georgiana Gavrilă
Maria-Georgiana Gavrilă
CACarmen Valeria Albu
Carmen Valeria Albu
BABogdan Cristian Albu
Bogdan Cristian Albu
EBEmilia Burada
Emilia Burada
RSRaluca Elena Sandu
Raluca Elena Sandu
RSRoxana Surugiu
Roxana Surugiu
The management of multiple sclerosis (MS) is shifting from a phenotype-based framework toward a biologically driven precision medicine model, as conventional magnetic resonance imaging (MRI) inadequately captures smoldering inflammation and progression independent of relapse activity (PIRA). This systematic review aimed to synthesize current evidence on the diagnostic and prognostic utility of fluid biomarkers in distinguishing acute inflammatory injury from chronic neurodegeneration. A comprehensive search of Web of Science, PubMed, and Scopus (January 2020–September 2025) identified 28 eligible studies including 7775 participants (6365 MS patients and 1410 controls). Biomarkers derived from serum, plasma, cerebrospinal fluid (CSF), and stool were evaluated in relation to clinical disability measured using the Expanded Disability Status Scale (EDSS) and magnetic resonance imaging (MRI) outcomes. Neurofilament light chain (NfL) consistently predicted acute inflammatory activity, gadolinium-enhancing lesions, and relapse-associated worsening, but levels were reduced by high-efficacy therapies and did not reliably predict PIRA. In contrast, glial fibrillary acidic protein (GFAP) was associated with astrogliosis, disability progression, and retinal thinning, even in patients with low inflammatory activity. Additional CSF, metabolic, and immunologic markers correlated with neurodegeneration and disease severity. Nevertheless, broader clinical use will require greater assay standardization, improved consistency across cohorts, and validation in prospective longitudinal studies. These findings compel a shift toward a multi-biomarker model to guide personalized therapeutic strategies and develop targeted neuroprotective treatments for progressive multiple sclerosis.

8 November 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
MGMaria-Georgiana Gavrilă
Maria-Georgiana Gavrilă
CACarmen Valeria Albu
Carmen Valeria Albu
EBEmilia Burada
Emilia Burada
RSRoxana Surugiu
Roxana Surugiu
BABogdan Cristian Albu
Bogdan Cristian Albu
RSRaluca Elena Sandu
Raluca Elena Sandu
Oxidative stress connects the inflammatory and the neurodegenerative components of multiple sclerosis, and redox markers have been proposed both for monitoring the disease and as targets for treatment. Individual studies, however, have reached divergent conclusions. In this systematic review, we searched PubMed, Scopus and Web of Science Core Collection for human studies published between 1 January 2019 and 11 April 2026 (PROSPERO CRD420261440796, registered retrospectively) and included 73 studies, 71 from the 23,027 database records and two from our earlier systematic review of fluid biomarkers in MS: forty-one case–control studies, six analytical cross-sectional studies, one prospective cohort, sixteen randomized trials and nine non-randomized or single-arm interventional studies. Circulating nitric oxide metabolites were the most consistent abnormality, higher in patients than in controls in all eight studies that measured them in blood, whether or not patients were receiving treatment, but not in cerebrospinal fluid. Antioxidant reserve was commonly reduced: total antioxidant capacity was lower in 13 of 20 studies, and thiols and glutathione peroxidase were lower in every study that measured them, whereas the antioxidant enzymes proved dysregulated rather than depleted, with superoxide dismutase tending to rise. Protein oxidation was raised in most cohorts, but advanced oxidation protein products, which discriminated patients from controls with an area under the curve of 0.948 in one cohort, were unchanged or lower in two others. Direction of change depended strongly on the compartment sampled and the assay used. 8-Hydroxy-2′-deoxyguanosine was higher in cerebrospinal fluid and urine but lower in serum. In two cohorts, antioxidant capacity measured with the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radical-scavenging assay (ABTS) and with the ferric reducing ability of plasma assay (FRAP) diverged in the same samples, in opposite directions. Antioxidant supplements and disease-modifying therapies altered redox status in most interventional studies, whereas the two exercise trials disagreed, and the changes were frequently transient and did not always accompany clinical improvement. Rated using a GRADE-informed approach adapted for this type of synthesis, the certainty of the evidence is very low for every marker assessed; nitric oxide metabolites, cerebrospinal fluid antioxidative capacity and total antioxidant capacity, measured by a specified assay, are the most reasonable candidates for prospective validation, and none is ready for clinical practice.